NRPR Nutri Pharmaceuticals Research Inc (PK)

Nutri Pharmaceuticals Research Inc. (Pink Sheets: NRPR), a leading developer and marketer of powdered nutritional ingredients, announced that it has appointed Farmington, Utah-based CornerStone Research and Development Inc., a consolidating entity of Mitsui & Co. (USA) Inc. and certified contract manufacturer and ingredient supplier, as the exclusive distributor for specialty O2P Powders from NPRI for the nutraceutical market. Product quotas for the first year must total at least $750,000 and escalate each year thereafter. According to NPRI President Godfrey Yew, "CornerStone is one of the preeminent custom manufacturers of nutritional and herbal formulations in capsules, tablets and powder forms, as well as the associated packaging services required to bring these products to market. With the addition of O2P Powders, CornerStone will now be able to offer their customers and the end consumer a range of powdered bio-active products that were once only available in liquid or semi-solid form." Commenting on the agreement, CornerStone President Steve Hatchett stated, "This is another strategic step in our efforts to offer our clients and the industry unique, value-building products. Having a unique family of bio-actives, powdered by the O2P technology, will enable us to offer food marketers, nutraceutical manufacturers and cosmetic producers the ability to incorporate the active ingredients found in many fatty acids, including the anti-oxidant properties found in nutritional oils. In this way, they will now be able to offer unique, efficacious and patentable products, whether as a functional food or beverage, dietary supplement or cosmeceutical." About NPRI Nutri Pharmaceuticals Research Inc. (www.o2p.us) provides a wide range of powdered oils for functional food, food supplement, dietary supplement, cosmetics, pet food and animal feed applications. The company is one of a select few to be awarded the prestigious Nutrition Business Journal "Product Merit Award" for its patent-pending O2P (TM) Powderization Process. At the heart of its oil powders is the O2P Oil-to-Powder technology. This patent-pending process converts most edible oils, gels or pastes into a free-flowing powder without affecting the isomeric structure, fatty acid profile, color, taste or aroma of the base oil. O2P does not rely on traditional techniques that utilize extremes in heat or cold, or micro-encapsulation technology. This facilitates food marketing and supplement producers' ability to create functional foods and nutraceuticals by adding anti-oxidants, specific EFAs or other fatty acids such as EPA, GLA, DHA and CLA to assist in maintaining specific health issues. The company currently offers more than 50 shelf-stable powders. The company can also apply O2P technology to a third party's oil, paste or gel through an arrangement called tolling. Based in Las Vegas, the company has representative sales offices near Chicago, Amsterdam, Guatemala City and Bangkok. Nutri Pharmaceuticals Research Inc. shares are currently traded in the United States on the "NQB (National Quotation Bureau) Pinksheets" under the symbol NRPR.PK. About CornerStone Research and Development CornerStone Research and Development (CRD) is the one of the largest nutraceutical contract manufactures in the world with more than 120,000 square feet of space. CRD provides full turnkey product manufacturing for its clients including research, formulation, product development, blending, tableting, encapsulation, packeting, bottling, blistering, analytical testing and fulfillment. Due to its TGA certification, CRD produces products for its clients that ship to more than 22 countries around the world, including Asia, North and South America and Europe. Forward-Looking Statements The words "believe," "expect," "anticipate" and other similar expressions generally identify forward-looking statements. Forward-looking statements are based on the company's current expectations and are subject to market, competitive and regulatory factors and the other risks and uncertainties indicated from time to time in the company's filings with the Securities and Exchange Commission. Actual results can differ materially. The company makes no commitment to disclose any revisions to forward-looking statements.